Centuria Capital (ASX:CNI) taps A$300m to chase the AI Factory re-rate
Centuria Capital Group (ASX:CNI) launches a A$300m raise at A$2.00 to accelerate ResetData AI Factories…
- ASX: CVB
CurveBeam AI
Share Price and News
ASX BIG FOUR - LIVE SNAPSHOT
SELL
Whitehaven Coal
(ASX:WHC)
Paul Flynn
01/03/2026
$8.7m
BUY
Elixir Energy
(ASX:EXR)
Featured
SELL
Aspen Group
(ASX:APZ)
David Dixon
03/03/2026
$11.4m
BUY
Lovisa
(ASX:LOV)
Brett Blundy
04/03/2026
$6.8m
— Company Overview
About CurveBeam AI
CurveBeam AI (ASX:CVB) is the leading medical technology company in the development and commercialization of sophisticated medical computed tomography scanners. Founded to change the face of diagnostic imaging, CurveBeam AI has positioned itself at the forefront of medical innovation. HiRise is the flagship product, a third-generation CT scanner that had been FDA cleared since 2020. HiRise represents the leading edge of imaging technology, designed for high-resolution scans with a precision yet to be paralleled. Not limiting itself to the development of hardware, CurveBeam AI develops intelligent AI algorithms and embeds them into its scanners. These algorithms not only improve the efficiency of the HiRise but also will be released as separate products in the very near future. CurveBeam AI converges premier imaging with strong AI-driven insights, thereby freeing up a gamut of innovations in medical diagnostics and improving patient outcomes across the healthcare sector.
History of CurveBeam AI
CurveBeam AI as a company was only founded in 2022 and listed on the ASX in 2023 as part of an M&A deal of StraxCorp and CurveBeam – the former bringing the BMD (Bone Mineral Density) algorithms and the latter bringing the physical scanners. The former company was founded in 2009 when its founder Arun Singh (who is still part of the company today), broke his foot and found scanners could only guess the extent of his injuries as they could only work with the patient lying down and this is unideal for foot injuries and while X-rays could be done upright, they were only 2D. The first FDA clearance was in 2012 and the latest generation was approved in 2020. Also in 2020, then president elect Joe Biden underwent a scan using CVB following his suffering of a hairline foot fracture. The company’s IPO came in 2023 during which it raised $25m. In the years immediately following the listing through 2024 and into 2025, CurveBeam AI reported revenue growth and strategic progress. The company also expanded commercial agreements such as a distribution and referral deal in Australia and New Zealand with medical device major Stryker. Despite progress, the company remained loss-making, though operating losses and cash burn were reduced compared to earlier periods. But in late 2025 and early 2026, more progress was made. the company signed a 10-year exclusive partnership with a Chinese consortium led by Shandong Weigao’s orthopaedic division to commercialise its WBCT and AI products across China and neighbouring territories, including potential equity investment totaling up to A$10 million and royalty arrangements.
- Free Report
Get Our Full ASX Stock Analysis Report
Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.
— Forward View
Future Outlook of CurveBeam AI (ASX:CVB)
Looking ahead, CurveBeam’s future outlook hinges on many factors. The most obvious of which is product adoption and growth – continued traction for HiRise and related SaaS AI modules in major markets (U.S., Europe, China) will be central. Success in China, if regulatory and commercial milestones are achieved, could drive significant revenue expansion. Agreements with established distributors and clinical partners will also improve commercial reach, but execution will be key.
— Our Assessment
Is CurveBeam AI (ASX:CVB) a Good Stock to Buy?
CurveBeam AI may appeal to investors comfortable with speculative, early-stage medical technology stocks with long-term potential, but it also carries significant execution and growth risk. Prospective investors should assess personal risk tolerance, stay updated on regulatory and market developments, and consider seeking advice from a qualified financial adviser before making investment decisions. CurveBeam AI is widely regarded in the ASX small-cap segment as a high-risk, high-upside speculative investment rather than a stable, low-risk stock. It operates in a competitive med-tech space where long sales cycles, regulatory requirements and the need for capital growth investment introduce execution risk. Share price performance has reflected volatility since IPO, and while strategic partnerships provide validation, the business is not yet consistently profitable and remains dependent on future adoption and funding.
— Our Stock Analysis
Related Articles
Has the SpaceX share price already peaked at $225?
On 16 June, just two trading days after the biggest float in the history of…
Norwood Systems (ASX:NOR) lands £150k UK telco pilot for OpenSpan
Norwood Systems (ASX:NOR) has signed a £150,000 paid pilot with a major UK telco for…
SpaceX (NSDQ:SPCX) The Most Misunderstood US $2T IPO in Decades
Should you buy SpaceX
SpaceX is becoming one of the most misunderstood IPOs in market…
Qualcomm in Talks to Buy Tenstorrent for US$10bn, Lifting 3 ASX AI Chip Stocks
KEY POINTS
Qualcomm (NASDAQ:QCOM) is in talks to buy AI chip startup Tenstorrent for…
Southern Cross Electrical (ASX:SXE) Raises $150m and Upgrades Guidance as Data Centre Demand Surges
KEY POINTS
Southern Cross Electrical (ASX:SXE) came back from a trading halt with a…
— Faq
Frequently Asked Questions
What is CurveBeam AI's HiRise?
HiRise is a point of care CT scanner that uses Cone Beam Technology and is functional – Weight Bearing. These features allow medical professionals (such as orthopaedic specialists) to do their job better by generating better images more likely to capture medical ailments and do so faster than competing technologies.
What's the big deal about 'weight-bearing' imaging?
It exposes injuries that otherwise wouldn’t be seen on scans when patients are in positions that don’t require them to put weight on the body part in question.
What is Bone Mineral Density?
Bone Mineral Density, is the volume of calcium and other minerals in a given area of bone. The denser the bones are, and thus less likely to fracture. Bones become less dense as we age and/or develop medical conditions and the lower the BMD, the more fragile these are. BMD is widely used to diagnose or monitor osteoporosis as well as to risk the assessment of fractures.
Why would customers want CurveBeam's solutions?
Because they can ensure more time and money for the doctors, since: There is lower capex than for traditional CT scanners, There are faster and immediate results (point of care scanning) and the provider can make a solid margin on the products even with minimal reimbursed scans per day.
Did Joe Biden use CurveBeam's scanners?
Yes, specifically PedCat (an earlier generation). Just prior to his inauguration, Biden suffered a hairline foot fracture and underwent a weight bearing CT scan using PedCat to monitor the fracture’s healing. It was not a big deal just because of Biden’s status nor that it confirmed a hairline fracture, but also that the initial X-Ray did not show any obvious injury because it was too small to be picked up.
Stay Sharp on the ASX
Weekly research. Independent analysis. No noise.
Free forever · Unsubscribe anytime
